Trial Profile

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC-study) - a Phase I/II Trial

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms INEC

Most Recent Events

01 Jul 2023 Results presented at the 25th World Congress on Gastrointestinal Cancer
14 Oct 2021 Status changed from recruiting to active, no longer recruiting.
02 Mar 2021 Planned number of patients changed from 54 to 30.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com